COMMUNIQUÉS West-GlobeNewswire

Artios Reports Randomized Phase 2a Study of Low Dose Alnodesertib Plus Gemcitabine Achieves Primary Endpoint in Platinum-Resistant Ovarian Cancer
02/03/2026
Low dose alnodesertib plus gemcitabine met the primary endpoint of progression-free survival (PFS) versus gemcitabine alone in patients with platinum-resistant high-grade serous ovarian cancer Study provides additional [...]
Ardena Appoints Paul Edwards as Chief People Officer
02/03/2026
Ghent, Belgium – March 2, 2026 – Ardena, a specialist pharmaceutical contract development and manufacturing organizatin (CDMO) and bioanalytical contract research organization (CRO) advancing precision medicines, today [...]
Tectonic Therapeutic to Participate in March Investor Conferences
02/03/2026
WATERTOWN, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic , Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and [...]
Humacyte To Participate in Upcoming Investor Conferences
02/03/2026
DURHAM, N.C., March 02, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, [...]
UroGen Announces ZUSDURI™ Launch is On-Track and Reports Fourth Quarter and Full Year 2025 Financial Results
02/03/2026
Commercial launch is on-track for ZUSDURI™, the first and only FDA-approved medication for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC); net sales in 2025 were $15.8 [...]
Pacira BioSciences Presents Two Real-World Studies from Its Innovations in Genicular Outcomes Registry (IGOR)
02/03/2026
-- Studies highlight the clinical effectiveness of EXPAREL for total knee arthroplasty and long-term pain management with iovera º for patients with osteoarthritis (OA) of the knee -- -- Data presented at the American [...]
Cadrenal Therapeutics Highlights Recent 12-LOX Inhibitor Platform Expansion
02/03/2026
Encouraging data for CAD-1005 in Phase 2 HIT Study EOP2 scheduled for Q1 for top-priority indication Additional acute and chronic opportunities for 12-LOX inhibition beyond HIT PONTE VEDRA, Fla., March 02, 2026 (GLOBE [...]
Replimune to Present at Two Upcoming Investor Conferences
02/03/2026
WOBURN, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that members [...]
Emory Researchers Demonstrate the Power of Dynamic Digital Radiography to Quantify Functional Outcomes After Total Shoulder Arthroplasty
02/03/2026
WAYNE, N.J., March 02, 2026 (GLOBE NEWSWIRE) -- Konica Minolta Healthcare Americas, Inc. congratulates Emory Healthcare researchers, led by Dr. Eric R. Wagner, on their recently published study comparing two well- [...]
Picard Medical / SynCardia Showcases Leadership in Total Artificial Heart Therapy at Technology and Heart Failure Therapeutics Conference
02/03/2026
New data highlight additional benefits beyond survival with the SynCardia Total Artificial Heart and preclinical progress for the next-generation Emperor system TUCSON, Ariz., March 02, 2026 (GLOBE NEWSWIRE) -- Picard [...]
Collegium to Participate in Upcoming Investor Conferences
02/03/2026
STOUGHTON, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that its management will participate in the following investor conferences: Leerink Partners Global [...]
Xilio Therapeutics to Present at the Leerink Partners Global Healthcare Conference
02/03/2026
WALTHAM, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer [...]
Galecto to Participate in Leerink Partners 2026 Global Healthcare Conference
02/03/2026
BOSTON, March 02, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biotechnology company working to redefine care for people with hematologic disorders, today announced that company management will participate [...]
Elutia Selects Pete Ligotti as CCO to Lead the Commercial Launch of NXT-41x and Transform Post-Mastectomy Care in the $1.5B U.S. Breast Surgery Market
02/03/2026
GAITHERSBURG, Md., March 02, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced the appointment of Pete Ligotti as Chief [...]
Health Catalyst to Announce Fourth Quarter and Year End 2025 Operating Results and Host Conference Call on Thursday, March 12, 2026
02/03/2026
SALT LAKE CITY, March 02, 2026 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, will release its [...]
Jupiter Neurosciences to Present at BIO Investment and Growth Summit 2026
02/03/2026
Advancing FDA-Cleared Phase IIa Parkinson’s Program Targeting Neuroinflammation Dual-Path Strategy Combines Clinical Development with Revenue-Generating Nugevia ™ JUPITER, FL, March 02, 2026 (GLOBE NEWSWIRE) -- Jupiter [...]
HCW Biologics Regains Compliance with All Continued Listing Rules for Nasdaq Per Nasdaq Determination Letter
02/03/2026
MIRAMAR, Fla., March 02, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (Nasdaq: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel [...]
UroGen Announces Refinanced Term Loan Agreement with Pharmakon Advisors
02/03/2026
Opportunistic refinancing meaningfully reduces cost of capital with 8.25% fixed interest rate and extends amortization period to Q1 2030 $200 million funded at closing to refinance the existing $125 million debt [...]
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/03/2026
WALTHAM, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living [...]

Pages